patients with bmi ≥30. patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.

patients with bmi ≥30. patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.